Literature DB >> 27454352

Detection of 2-hydroxyglutarate in brain tumors by triple-refocusing MR spectroscopy at 3T in vivo.

Zhongxu An1, Sandeep K Ganji1, Vivek Tiwari1, Marco C Pinho1,2, Toral Patel3,4, Samuel Barnett4,5, Edward Pan3,4,6, Bruce E Mickey4,6,7, Elizabeth A Maher3,6,7,8, Changho Choi1,2,6.   

Abstract

PURPOSE: To test the efficacy of triple-refocusing MR spectroscopy (MRS) for improved detection of 2-hydroxyglutarate (2HG) in brain tumors at 3T in vivo.
METHODS: The triple-refocusing sequence parameters were tailored at 3T, with density-matrix simulations and phantom validation, for enhancing the 2HG 2.25-ppm signal selectivity with respect to the adjacent resonances of glutamate (Glu), glutamine (Gln), and gamma-aminobutyric acid (GABA). In vivo MRS data were acquired from 15 glioma patients and analyzed with LCModel using calculated basis spectra. Metabolites were quantified with reference to water.
RESULTS: A triple-refocusing sequence (echo time = 137 ms) was obtained for 2HG detection. The 2HG 2.25-ppm signal was large and narrow while the Glu and Gln signals between 2.2 and 2.3 ppm were minimal. The optimized triple refocusing offered improved separation of 2HG from Glu, Gln and GABA when compared with published MRS methods. 2HG was detected in all 15 patients, the estimated 2HG concentrations ranging from 2.4 to 15.0 mM, with Cramer-Rao lower bounds of 2%-11%. The 2HG estimates did not show significant correlation with total choline.
CONCLUSION: The optimized triple refocusing provides excellent 2HG signal discrimination from adjacent resonances and may confer reliable in vivo measurement of 2HG at relatively low concentrations. Magn Reson Med 78:40-48, 2017.
© 2016 International Society for Magnetic Resonance in Medicine. © 2016 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  1H MRS; 2-hydroxyglutarate; 3T; glioma; human brain tumor; isocitrate dehydrogenase; triple refocusing

Mesh:

Substances:

Year:  2016        PMID: 27454352      PMCID: PMC5266748          DOI: 10.1002/mrm.26347

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  31 in total

1.  In vivo detection of citrate in brain tumors by 1H magnetic resonance spectroscopy at 3T.

Authors:  Changho Choi; Sandeep K Ganji; Akshay Madan; Keith M Hulsey; Zhongxu An; Song Zhang; Marco C Pinho; Ralph J DeBerardinis; Robert M Bachoo; Elizabeth A Maher
Journal:  Magn Reson Med       Date:  2013-10-01       Impact factor: 4.668

2.  Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.

Authors:  Ovidiu C Andronesi; Grace S Kim; Elizabeth Gerstner; Tracy Batchelor; Aria A Tzika; Valeria R Fantin; Matthew G Vander Heiden; A Gregory Sorensen
Journal:  Sci Transl Med       Date:  2012-01-11       Impact factor: 17.956

3.  T2 measurement of J-coupled metabolites in the human brain at 3T.

Authors:  Sandeep K Ganji; Abhishek Banerjee; Aditya M Patel; Yan D Zhao; Ivan E Dimitrov; Jeffrey D Browning; E Sherwood Brown; Elizabeth A Maher; Changho Choi
Journal:  NMR Biomed       Date:  2011-08-15       Impact factor: 4.044

4.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

5.  IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma.

Authors:  Morteza Esmaeili; Bob C Hamans; Anna C Navis; Remco van Horssen; Tone F Bathen; Ingrid S Gribbestad; William P Leenders; Arend Heerschap
Journal:  Cancer Res       Date:  2014-07-08       Impact factor: 12.701

6.  An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Authors:  Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff
Journal:  Science       Date:  2013-04-04       Impact factor: 47.728

7.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

Review 8.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

9.  2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.

Authors:  Changho Choi; Sandeep K Ganji; Ralph J DeBerardinis; Kimmo J Hatanpaa; Dinesh Rakheja; Zoltan Kovacs; Xiao-Li Yang; Tomoyuki Mashimo; Jack M Raisanen; Isaac Marin-Valencia; Juan M Pascual; Christopher J Madden; Bruce E Mickey; Craig R Malloy; Robert M Bachoo; Elizabeth A Maher
Journal:  Nat Med       Date:  2012-01-26       Impact factor: 53.440

10.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Authors:  Patrick S Ward; Jay Patel; David R Wise; Omar Abdel-Wahab; Bryson D Bennett; Hilary A Coller; Justin R Cross; Valeria R Fantin; Cyrus V Hedvat; Alexander E Perl; Joshua D Rabinowitz; Martin Carroll; Shinsan M Su; Kim A Sharp; Ross L Levine; Craig B Thompson
Journal:  Cancer Cell       Date:  2010-02-18       Impact factor: 38.585

View more
  18 in total

1.  Echo-planar spectroscopic imaging with dual-readout alternated gradients (DRAG-EPSI) at 7 T: Application for 2-hydroxyglutarate imaging in glioma patients.

Authors:  Zhongxu An; Vivek Tiwari; Sandeep K Ganji; Jeannie Baxter; Michael Levy; Marco C Pinho; Edward Pan; Elizabeth A Maher; Toral R Patel; Bruce E Mickey; Changho Choi
Journal:  Magn Reson Med       Date:  2017-08-22       Impact factor: 4.668

2.  Distinction of the GABA 2.29 ppm resonance using triple refocusing at 3 T in vivo.

Authors:  Vivek Tiwari; Zhongxu An; Yiming Wang; Changho Choi
Journal:  Magn Reson Med       Date:  2018-02-14       Impact factor: 4.668

3.  Measurement of glycine in healthy and tumorous brain by triple-refocusing MRS at 3 T in vivo.

Authors:  Vivek Tiwari; Zhongxu An; Sandeep K Ganji; Jeannie Baxter; Toral R Patel; Edward Pan; Bruce E Mickey; Elizabeth A Maher; Marco C Pinho; Changho Choi
Journal:  NMR Biomed       Date:  2017-05-26       Impact factor: 4.044

4.  Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma.

Authors:  Evan Neill; Tracy Luks; Manisha Dayal; Joanna J Phillips; Arie Perry; Llewellyn E Jalbert; Soonmee Cha; Annette Molinaro; Susan M Chang; Sarah J Nelson
Journal:  J Neurooncol       Date:  2017-01-25       Impact factor: 4.130

5.  Optimization of spectrally selective 180° radiofrequency pulse timings in J-difference editing (MEGA) of lactate.

Authors:  Sandeep K Ganji; Zhongxu An; Vivek Tiwari; Yongmin Chang; Toral R Patel; Elizabeth A Maher; Changho Choi
Journal:  Magn Reson Med       Date:  2021-10-17       Impact factor: 4.668

Review 6.  An Update on the Approach to the Imaging of Brain Tumors.

Authors:  Katherine M Mullen; Raymond Y Huang
Journal:  Curr Neurol Neurosci Rep       Date:  2017-07       Impact factor: 5.081

7.  3D high-resolution imaging of 2-hydroxyglutarate in glioma patients using DRAG-EPSI at 3T in vivo.

Authors:  Zhongxu An; Vivek Tiwari; Jeannie Baxter; Michael Levy; Kimmo J Hatanpaa; Edward Pan; Elizabeth A Maher; Toral R Patel; Bruce E Mickey; Changho Choi
Journal:  Magn Reson Med       Date:  2018-09-14       Impact factor: 4.668

8.  In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting.

Authors:  Valeria Cuccarini; Luigi Antelmi; Bianca Pollo; Rosina Paterra; Chiara Calatozzolo; Anna Nigri; Francesco DiMeco; Marica Eoli; Gaetano Finocchiaro; Greta Brenna; Irene Tramacere; Maria Grazia Bruzzone; Elena Anghileri
Journal:  Neurol Sci       Date:  2019-10-24       Impact factor: 3.307

9.  Spectral editing in 1 H magnetic resonance spectroscopy: Experts' consensus recommendations.

Authors:  In-Young Choi; Ovidiu C Andronesi; Peter Barker; Wolfgang Bogner; Richard A E Edden; Lana G Kaiser; Phil Lee; Małgorzata Marjańska; Melissa Terpstra; Robin A de Graaf
Journal:  NMR Biomed       Date:  2020-09-18       Impact factor: 4.044

Review 10.  Glioblastoma Metabolomics-In Vitro Studies.

Authors:  Karol Jaroch; Paulina Modrakowska; Barbara Bojko
Journal:  Metabolites       Date:  2021-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.